Content about Attention-deficit hyperactivity disorder

February 25, 2011
Watson seeks regulatory approval for generic Adderall XR

Watson Labs is hoping to be the first to market a generic version of a popular drug for attention deficit hyperactivity disorder.

PHILADELPHIA — Watson Labs is hoping to be the first to market a generic version of a popular drug for attention deficit hyperactivity disorder.

British drug maker Shire announced Thursday that it had received notification that Watson filed for regulatory approval of a version of Adderall XR (dextroamphetamine and amphetamine) capsules with the Food and Drug Administration. Watson’s application contained a Paragraph IV certification, a legal assertion that the patent covering Adderall XR is invalid, unenforceable or won’t be infringed by Watson’s product.

January 10, 2011
Kapvay designed to treat ADHD

Drug maker Shionogi has launched a new medication for attention deficit hyperactivity disorder, the company said Monday.

FLORHAM PARK, N.J. — Drug maker Shionogi has launched a new medication for attention deficit hyperactivity disorder, the company said Monday.

Shionogi announced the launch of Kapvay (clonidine hydrochloride), an extended-release drug for treating ADHD in children and adolescents. The company said the drug was the only ADHD treatment approved as an add-on to stimulant medications, though it can be used alone as well.

December 28, 2010
Report: More than a quarter of U.S. kids take at least one chronic med

Health professionals worry that little is known about the long-term effects of many drugs — which have been tested extensively on adult-patient populations — on children.

NEW YORK — More than 25% of children and teens take at least one medication on a daily basis, and nearly 7% are on two or more drugs, the Wall Street Journal reported Tuesday, citing 2009 data from Medco Health Solutions. Drawing additional data from IMS Health, the article noted that prescriptions for hypertension in people under the age of 20 years could reach 5.5 million for 2010 by the time year-end results are tabulated, which would mark a rise of 17% since 2007. 

November 14, 2010
FDA approves ADHD drug for adolescents

The Food and Drug Administration has approved an attention deficit hyperactivity disorder drug for use...

PHILADELPHIA — The Food and Drug Administration has approved an attention deficit hyperactivity disorder drug for use in adolescents.

British drug maker Shire announced Monday the approval of Vyvanse (lisdexamfetamine dimesylate) capsules for patients aged 13 to 17. The drug was already approved for children ages 6 years to 12 years and adults.

October 27, 2010
Symposium addresses sexual dysfunction among women

Sexual dysfunction often is conceived as a male phenomenon, but it frequently affects women as...

NEW YORK Sexual dysfunction often is conceived as a male phenomenon, but it frequently affects women as well, and for a wide variety of reasons.

 

October 3, 2010
Shionogi gets FDA approval for Kapvay

The Food and Drug Administration has approved a nonstimulant drug for treating attention deficit hyperactivity...

FLORHAM PARK, N.J. The Food and Drug Administration has approved a nonstimulant drug for treating attention deficit hyperactivity disorder.

 

Shionogi announced Monday the approval of Kapvay (clonidine hydrochloride), an extended-release drug for treating ADHD in children and adolescents ages 6 to 17 years. The company said Kapvay was the only formulation of clonidine hydrochloride approved for treating ADHD and the first ADHD treatment approved for use as an add-on therapy to stimulant drugs.

 

 

August 31, 2010
FDA approves Sun's generic Strattera

A generic drug maker has received regulatory approval for its version of an attention deficit...

MUMBAI, India A generic drug maker has received regulatory approval for its version of an attention deficit hyperactivity disorder treatment.

Sun Pharmaceutical Industries' subsidiary has received approval to market its generic version of Strattera (atomoxetine hydrochloride capsules), an ADHD drug for children ages 6 years and older, as well as teens and adults. Strattera is made and marketed by Eli Lilly.

Annual sales of branded and generic atomoxetine hydrochloride capsules are estimated to be more than $530 million.

August 10, 2010
Curemark gets nod to start late-stage trial for ADHD drug

The Food and Drug Administration has approved a late-stage clinical trial of a drug for...

July 19, 2010
PhRMA: 313 mental disorder treatments are in development

More than 300 medications for treating mental disorders are in development, according to a new...

WASHINGTON More than 300 medications for treating mental disorders are in development, according to a new report by a pharmaceutical industry lobbying group.

 

July 6, 2010
FDA approves expanded use of Daytrana

The Food and Drug Administration has approved a drug made by Shire for treating attention...

May 20, 2010
Shire: Intuniv users experience 'significant' improvements with ADHD symptoms

British drug maker Shire presented late-stage clinical study data at a psychiatric meeting Friday indicating...

May 19, 2010
Shire to present Vyvanse, Intuniv studies at psychiatrist meetings

British drug maker Shire will present data on two attention deficit hyperactivity disorder treatments in...

March 3, 2010
Shire given market exclusivity for ADHD drug

The U.S. District Court for the District of Columbia has upheld a decision by the...